Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Vorasidenib with Low-Fat Meal and Ciprofloxacin in Healthy Subjects
NCT05843708Phase 1Completed
- Sponsor
- Servier
- Start
- Apr 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vorasidenib in glioma, astrocytoma and Oligodendroglioma (OG) (4 arms), sponsored by Servier. Primary endpoints: Maximum Plasma Concentration (Cmax) of Vorasidenib, Time to Maximum Plasma Concentration (Tmax) of Vorasidenib and 2 more. Started Apr 2023; status: completed.
02
Drugs
vorasidenib
03
Conditions
gliomaastrocytomaOligodendroglioma (OG)
Beyond the preview
Go deeper on NCT05843708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05843708.